Welcome to our dedicated page for Arcus Biosciences news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Biosciences stock.
Arcus Biosciences, Inc. (NASDAQ: RCUS) is a cutting-edge, clinical-stage biopharmaceutical company dedicated to developing innovative immunotherapies for cancer treatment. Founded in 2015 by experienced researchers from the biotechnology and pharmaceutical sectors, Arcus is based in the San Francisco Bay Area, a hub for biotechnological innovation.
Arcus Biosciences focuses on leveraging insights in immunology to create new cancer therapeutics. The company is particularly known for its work on the ATP-adenosine pathway, a significant driver of immunosuppression in the tumor microenvironment. Their aim is to optimize small-molecule immuno-oncology product candidates that could revolutionize cancer treatment.
Arcus has a robust product pipeline that includes several promising candidates such as Domvanalimab, Etrumadenant, AB598, and Casdatifan. These drugs target different aspects of the immune system to either modulate cellular processes in cancer or directly combat tumor growth.
Significant achievements include successful clinical trials for treating various types of cancers, including lung, colorectal, and pancreatic cancers. The company operates through a single segment focused on the development and commercialization of its immunotherapies.
Arcus prides itself on maintaining an internal team of highly skilled professionals rather than outsourcing its research and development efforts. This approach ensures the highest quality and innovation in their drug discovery process.
With ongoing partnerships and collaborations, notably with Gilead Sciences, Arcus is well-positioned to bring its innovative therapies to market, providing new hope for patients with cancer.
Gilead Sciences and Arcus Biosciences reported promising results from the ARC-7 Study, focusing on first-line, metastatic non-small cell lung cancer (NSCLC). The study demonstrated a 35-45% reduction in the risk of progression or death and a significant improvement in median progression-free survival (PFS) with the combination therapies compared to zimberelimab monotherapy. The objective response rates showed a positive trend, with the doublet and triplet arms showing 41% and 40%, respectively. Further detailed results will be presented on December 20.
Arcus Biosciences announced the grant of stock options and restricted stock units to five new employees. A total of 8,200 shares can be purchased at an exercise price of $31.00, the closing price on December 8, 2022. Additionally, 4,100 restricted stock units were granted. These awards are part of the company’s 2020 Inducement Plan, approved in January 2020. Arcus Biosciences focuses on developing innovative cancer therapies and has expedited six investigational medicines into clinical studies.
Gilead Sciences (GILD) and Arcus Biosciences (RCUS) announced positive results from the fourth interim analysis of the Phase 2 ARC-7 study for first-line metastatic non-small cell lung cancer (NSCLC). The analysis, conducted with a data cutoff on August 31, 2022, included 150 patients and demonstrated that both domvanalimab combinations significantly outperformed zimberelimab monotherapy across multiple efficacy measures, including progression-free survival (PFS). Results will be presented at the ASCO Monthly Plenary Series on December 20, 2022.
Gilead Sciences and Arcus Biosciences announced promising results from the fourth interim analysis of the Phase 2 ARC-7 study for first-line NSCLC patients. The study evaluates the effects of domvanalimab (anti-TIGIT) in combination with zimberelimab (anti-PD-1) versus zimberelimab alone. Results indicate significant clinical benefits across key efficacy measures, including progression-free survival (PFS). No unexpected safety issues were noted. Full results will be presented on December 20, 2022, at the ASCO Monthly Plenary Series.
Arcus Biosciences (NYSE:RCUS) will participate in a virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on November 30, 2022, at 11:20 a.m. Eastern Time. Investors can access the live webcast via the Investors & Media section of their website. Arcus is focused on developing innovative treatments for cancer, collaborating with global partners to expedite the development of first- or best-in-class medicines. Since its founding in 2015, Arcus has initiated clinical studies for six investigational medicines targeting critical pathways in cancer treatment.
Arcus Biosciences, Inc. (NYSE:RCUS) announced the granting of stock options and restricted stock units to nine new employees. A total of 13,700 options were granted at an exercise price of $24.69, the closing price on November 8, 2022, alongside 6,850 restricted stock units. These awards were made under the Company’s 2020 Inducement Plan, approved in January 2020. Arcus focuses on developing innovative cancer therapies through clinical studies on various investigational medicines targeting key biological pathways.
Arcus Biosciences reported its Q3 2022 financial results, revealing revenues of $33.6 million, up from $9.5 million in Q3 2021, driven by collaboration with Gilead. The company holds $1.2 billion in cash, sufficient to fund operations into 2026. Arcus is advancing its clinical pipeline, focusing on anti-TIGIT therapies with three Phase 3 trials for domvanalimab in lung cancer. A strategic amendment to the ARC-10 trial design now compares domvanalimab and zimberelimab to pembrolizumab, excluding a chemotherapy arm. The trial aims to define a new standard-of-care in NSCLC.
Arcus Biosciences, Inc. (NYSE:RCUS) announced the granting of options and restricted stock units to 14 new employees, totaling 35,200 shares at an exercise price of $26.15, the closing price on October 10, 2022. Additionally, 17,600 shares were awarded as restricted stock units. This award is part of the company’s 2020 Inducement Plan, which complies with NYSE regulations. Arcus focuses on developing innovative cancer therapies and has advanced six investigational medicines to clinical studies.
Arcus Biosciences, Inc. (NYSE:RCUS) announced the granting of stock options and restricted stock units to ten new employees, totaling 33,950 and 16,975 shares, respectively. The options were priced at $25.70, aligning with the closing price on September 8, 2022. This equity grant falls under the 2020 Inducement Plan, approved by the Board of Directors. Arcus is focused on developing innovative cancer therapies, with clinical studies underway for six investigational medicines targeting various biological pathways.
Arcus Biosciences (NYSE:RCUS) announced its participation in key investor conferences. The Citi 17th Annual BioPharma Conference will take place on September 7, 2022, in Boston, MA, featuring 1-on-1 meetings. Following this, the Morgan Stanley 20th Annual Global Healthcare Conference is scheduled for September 12, 2022, in New York, NY, with a fireside chat at 12:30 p.m. ET. A live webcast will be available on the Arcus website, with replays accessible afterward.
FAQ
What is the current stock price of Arcus Biosciences (RCUS)?
What is the market cap of Arcus Biosciences (RCUS)?
What does Arcus Biosciences, Inc. do?
Where is Arcus Biosciences located?
When was Arcus Biosciences founded?
What is the core focus of Arcus Biosciences' research?
What are some of Arcus Biosciences' main products?
What types of cancer does Arcus Biosciences target?
Does Arcus Biosciences outsource its research and development?
With whom does Arcus Biosciences have significant partnerships?
What makes Arcus Biosciences unique?